We identified 2 distinct discontinuous gliadin sequence sets that, when combined, significantly improved the sensitivity (IgG, 97%; IgA, 99%) and specificity (IgG, 98%; IgA, 100%) (P < .001) for the diagnosis of CD, in contrast to the first sets of peptides of gliadin sequences or current standard CD serologic testing with enzyme-linked immunosorbent assay kits, and the sensitivity and specificity of these current standard CD serologic testing shown in Fig 6A are similar to other previous studies.[18] These 2 distinct peptide sets are shown in S3 Table. This evidence concerns the gene CD79A and Cowden disease.